Your browser doesn't support javascript.
loading
[What attitude to women at high risk of breast cancer?] / Les femmes à haut risque de cancer du sein : quelle attitude ?
Livon, Doriane; Moretta, Jessica; Noguès, Catherine.
Afiliação
  • Livon D; Institut Paoli-Calmettes, oncogénétique clinique, département d'anticipation et de suivi du cancer, 232, boulevard Sainte-Marguerite, 13009 Marseille, France. Electronic address: livond@ipc.unicancer.fr.
  • Moretta J; Institut Paoli-Calmettes, oncogénétique clinique, département d'anticipation et de suivi du cancer, 232, boulevard Sainte-Marguerite, 13009 Marseille, France.
  • Noguès C; Institut Paoli-Calmettes, oncogénétique clinique, département d'anticipation et de suivi du cancer, 232, boulevard Sainte-Marguerite, 13009 Marseille, France; Aix-Marseille Université, IRD, SESSTIM, Inserm, 13007 Marseille, France.
Presse Med ; 48(10): 1092-1100, 2019 Oct.
Article em Fr | MEDLINE | ID: mdl-31706893
ABSTRACT
In France, breast cancer is the most common cancer among women and the leading cause of cancer deaths. Identifying women with a "high" or "very high" breast cancer risk, according the terminology of the Haute Autorité de Santé 2014 guidelines, is essential to offer them special cares in term of screening and prevention. Women genetically predisposed have a very high risk of breast cancer. During the oncogenetic specialist consultation, familial and personal history of cancer is taken into account to evaluate the risk of hereditary Breast/Ovarian syndrome and thus the need of a genetic screening. In 2017, a list of 13 genes involved in hereditary ovarian or breast cancer has been established in France (Genetic and Cancer Group - Unicancer). Women carrying a BRCA1, BRCA2, PALB2, TP53, CDH1, PTEN mutation have a higher risk of breast cancer and are considered as "high risk". Therefore, medical breast surveillance similar to carriers of BRCA1/BRCA2 mutation is recommended for these patients (INCa guidelines 2017). However a mutation in one of those genes is only identified in approximatively 10 % of the screened families. The oncogenetic specialist's assessment distinguishes families in which women remain at a "high" risk of breast cancer (HAS 2014 for screening) from those where women have a "very high" risk (INCa guidelines 2017 for screening and prevention).
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Predisposição Genética para Doença / Mutação Idioma: Fr Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Predisposição Genética para Doença / Mutação Idioma: Fr Ano de publicação: 2019 Tipo de documento: Article